Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Biodistribution and acute toxicity of a nanofluid containing manganese iron oxide nanoparticles produced by a mechanochemical process

Authors Bellusci M, La Barbera A, Padella F, Mancuso M, Pasquo A, Grollino MG, Leter G, Nardi E, Cremisini C, Giardullo P, Pacchierotti F

Received 22 October 2013

Accepted for publication 6 December 2013

Published 17 April 2014 Volume 2014:9(1) Pages 1919—1929


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Mariangela Bellusci,1 Aurelio La Barbera,1 Franco Padella,1 Mariateresa Mancuso,2 Alessandra Pasquo,2 Maria Giuseppa Grollino,2 Giorgio Leter,2 Elisa Nardi,3 Carlo Cremisini,3 Paola Giardullo,4 Francesca Pacchierotti2

1Technical Unit for Material Technologies, 2Technical Unit for Radiation Biology and Human Health, 3Technical Unit for Environmental Characterization, Prevention and Recovery, Agenzia Nazionale per le Nuove Tecnologie, l'Energia e lo Sviluppo Economico Sostenibile (ENEA), Casaccia Research Centre, Rome, Italy; 4Department of Radiation Physics, Marconi University, Rome, Italy

Abstract: Superparamagnetic iron oxide nanoparticles are candidate contrast agents for magnetic resonance imaging and targeted drug delivery. Biodistribution and toxicity assessment are critical for the development of nanoparticle-based drugs, because of nanoparticle-enhanced biological reactivity. Here, we investigated the uptake, in vivo biodistribution, and in vitro and in vivo potential toxicity of manganese ferrite (MnFe2O4) nanoparticles, synthesized by an original high-yield, low-cost mechanochemical process. Cultures of murine Balb/3T3 fibroblasts were exposed for 24, 48, or 72 hours to increasing ferrofluid concentrations. Nanoparticle cellular uptake was assessed by flow-cytometry scatter-light measurements and microscopy imaging after Prussian blue staining; cytotoxicity was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and colony-forming assays. After a single intravenous injection, in vivo nanoparticle biodistribution and clearance were evaluated in mice by Mn spectrophotometric determination and Prussian blue staining in the liver, kidneys, spleen, and brain at different posttreatment times up to 21 days. The same organs were analyzed for any possible histopathological change. The in vitro study demonstrated dose-dependent nanoparticle uptake and statistically significant cytotoxic effects from a concentration of 50 µg/mL for the MTT assay and 20 µg/mL for the colony-forming assay. Significant increases in Mn concentrations were detected in all analyzed organs, peaking at 6 hours after injection and then gradually declining. Clearance appeared complete at 7 days in the kidneys, spleen, and brain, whereas in the liver Mn levels remained statistically higher than in vehicle-treated mice up to 3 weeks postinjection. No evidence of irreversible histopathological damage to any of the tested organs was observed. A comparison of the lowest in vitro toxic concentration with the intravenously injected dose and the administered dose of other ferrofluid drugs currently in clinical practice suggests that there might be sufficient safety margins for further development of our formulation.

Keywords: biodistribution, biosafety, ICP-MS, Prussian blue staining, MnFe2O4 nanoparticles, ferrofluid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Association of BDNF Val66Met polymorphism with HPA and SAM axis reactivity to psychological and physical stress

Tsuru J, Tanaka Y, Ishitobi Y, Maruyama Y, Inoue A, Kawano A, Ikeda R, Ando T, Oshita H, Aizawa S, Masuda K, Higuma H, Kanehisa M, Ninomiya T, Akiyoshi J

Neuropsychiatric Disease and Treatment 2014, 10:2123-2133

Published Date: 11 November 2014

Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia

Kikuchi YS, Sato W, Ataka K, Yagisawa K, Omori Y, Kanbayashi T, Shimizu T

Neuropsychiatric Disease and Treatment 2014, 10:1973-1978

Published Date: 15 October 2014

Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure

Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant’Anna M, Kawamoto SY, Galvão E, Parker G, Fleck MP

Neuropsychiatric Disease and Treatment 2014, 10:1523-1531

Published Date: 19 August 2014

Fabrication of nanoadjuvant with poly-e-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity

Prashant CK, Bhat M, Srivastava SK, Saxena A, Kumar M, Singh A, Samim M, Ahmad FJ, Dinda AK

International Journal of Nanomedicine 2014, 9:937-950

Published Date: 12 February 2014

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012